The prognostic value of prostate-specific antigen (PSA) kinetics in primary high-volume metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with novel hormonal therapy agents is still unclear. Here, we retrospectively reviewed the data of 102 patients with primary high-volume mHSPC who received novel hormonal therapy agents. The median follow-up was 32.25 ± 14.51 months and the median nadir PSA (nPSA) was 0.20 (0.06, 11.71) ng/mL after treatment. The mean time to nPSA was 10.82 ± 7.27 months and 55 patients (53.9%) had a PSA-density (PSA-D) ≤ 0.08 at 3-months. Univariate and multivariate Cox regression analyses showed that the absence of visceral metastases, nPSA ≤ 0.2 and PSA-D ≤ 0.08 were independent prognostic factors for better PFS and OS (all P < 0.05). Moreover, patients with nPSA ≤ 0.2 and PSA-D ≤ 0.08 had the best PFS and OS, and the combination of the nPSA and PSA-D had a better predictive accuracy for PFS and OS than nPSA and PSA-D alone. Thus, Visceral metastases, nPSA and PSA-D were independent prognostic factors for primary high-volume mHSPC patients treated with novel hormonal therapy agents. Patients with lower nPSA and PSA-D had a best survival outcome, and the combination of nPSA and PSA-D had a better effect on prognosis predicting.
Scientific reports. 2024 Nov 04*** epublish ***
Yingchun Wang, Jie Suo, Bo Wang, Qunli Men, Dachuan Wang, Haibo Jing, Tao Li, Xiaodong Huang, Chenqing Wang, Xiaohui Luo, Yuquan Ju, Junjie Fan, Jianzhou Liu
Department of Urology, Baoji Central Hospital, #8 Jiangtan Road, Baoji, 721008, Shaanxi Province, People's Republic of China., Department of Urology, Baoji Central Hospital, #8 Jiangtan Road, Baoji, 721008, Shaanxi Province, People's Republic of China. ., Department of Urology, Baoji Central Hospital, #8 Jiangtan Road, Baoji, 721008, Shaanxi Province, People's Republic of China. .